BIO
$456.01
Bio-Rad Laboratories
$6.62
1.47%
Earnings Details
2nd Quarter June 2022
Thursday, July 28, 2022 4:17:00 PM
Tweet Share Watch
Summary

Bio-Rad Labs Guides to the High-end of Range

Bio-Rad Laboratories (BIO) reported 2nd Quarter June 2022 earnings of $3.38 per share on revenue of $691.1 million. The consensus earnings estimate was $2.46 per share on revenue of $682.6 million. Revenue fell 3.5% compared to the same quarter a year ago.

The company said it expects 2022 to be at the high-end of its previous guidance range of revenue of $2.95 billion to $2.98 billion. The current consensus revenue estimate is $2.85 billion for the year ending December 31, 2022.

Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Results
Reported Earnings
$3.38
Earnings Whisper
-
Consensus Estimate
$2.46
Reported Revenue
$691.1 Mil
Revenue Estimate
$682.6 Mil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Bio-Rad Reports Second-Quarter 2022 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022.

Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compared to $715.9 million reported for the second quarter of 2021. COVID-related revenue was approximately $33 million in the second quarter of 2022 versus approximately $69 million reported in the year-ago period. On a currency-neutral basis, quarterly sales increased 0.5 percent compared to the same period in 2021. Excluding COVID-related sales, revenue increased 5.7% on a currency-neutral basis.

Second-quarter gross margin was 57.3 percent compared to 56.1 percent for the second quarter of 2021.

Life Science segment net sales for the second quarter were $322.4 million, a decrease of 3.5 percent compared to the same period in 2021. On a currency-neutral basis, Life Science segment sales increased 0.5 percent compared to the same quarter in 2021. The currency-neutral sales increase was primarily due to increased sales of Process Chromatography and Protein Quantitation products.

Clinical Diagnostics segment net sales for the second quarter were $367.8 million, a decrease of 3.3 percent compared to the same period in 2021. On a currency-neutral basis, net sales were up 0.7 percent versus the same quarter last year. The currency-neutral sales increase was primarily driven by growth in the Quality Controls and the Immunohematology businesses.

Income from operations for the second quarter of 2022 was $120.2 million versus $124.8 million during the same quarter last year.

Net loss for the second quarter of 2022 was $927.2 million, or a loss of $31.12 per share, on a diluted basis, versus $914.1 million of net income, or $30.32 per share, on a diluted basis, during the same period in 2021. Net income (loss) amounts for the second quarter of 2022 and 2021 were primarily impacted by the recognition of changes in the fair market value of equity securities related to the holdings of the company’s investment in Sartorius AG.

The effective tax rate for the second quarter of 2022 was 24.2 percent, compared to 21 percent for the same period in 2021. The second-quarter 2022 effective tax rate was primarily affected by an unrealized loss in equity securities and the tax rate reported in Q2 of 2021 was primarily affected by an unrealized gain in equity securities.

“During the second quarter, we continued to see solid demand in our core Life Science and Clinical Diagnostics segments against the backdrop of the ongoing macroeconomic, geopolitical, and supply chain challenges,” said Norman Schwartz, Bio-Rad’s President, and Chief Executive Officer. “Looking to the second half of the year, while we expect the supply chain constraints to continue, we remain on track to achieve our full-year 2022 financial outlook.”

GAAP Results

Q2 2022

Q2 2021

Revenue (millions)

$691.1

$715.9

Gross margin

57.3%

56.1%

Operating margin

17.4%

17.4%

Net income (loss) (millions)

($927.2)

$914.1

Income (loss) per diluted share

($31.12)

$30.32

 

Non-GAAP Results

Q2 2022

Q2 2021

Revenue (millions)

$691.1

$715.9

Gross margin

57.9%

56.9%

Operating margin

18.8%

18.5%

Net income (millions)

$101.4

$106.6

Income per diluted share

$3.38

$3.54

A reconciliation between GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release. Non-GAAP adjustments include amortization of purchased intangibles; acquisition-related expenses and benefits; restructuring, impairment charges and gains and losses from change in fair market value of equity securities and loan receivable; gains and losses on equity-method investments; significant litigation charges or benefits and legal costs; and discrete income tax events and the income tax effect on these non-GAAP adjustments.

Non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS) are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Non-GAAP and Currency-Neutral Reporting.”

Non-GAAP net income for the second quarter of 2022 was $101.4 million, or $3.38 per share, on a diluted basis, compared to $106.6 million, or $3.54 per share, on a diluted basis, during the same period in 2021.

The non-GAAP effective tax rate for the second quarter of 2022 was 19 percent, compared to 21.5 percent for the same period in 2021. The lower rate in 2022 was driven by the geographical mix of earnings, as well as the benefit of a preferential tax rate related to export sales.

The following table represents a reconciliation of Bio-Rad’s reported net income (loss) and diluted income (loss) per share to non-GAAP net income and non-GAAP diluted income per share for the three and six months ended June 30, 2022, and 2021:

(in thousands, except per share data)

Three Months Ended
June 30,

Six Months Ended
June 30,

2022

2021

2022

 

2021

GAAP net income (loss)

($927,184)

$914,114

($4,296,797)

 

$1,891,528

Legal Settlements

-

-

-

 

(536)

Amortization of purchased intangibles

6,291

6,995

12,601

 

13,935

Legal matters

875

8,761

2,068

 

13,176

Acquisition related benefits

-

(40)

 

-

 

(40)

Restructuring benefits (costs)

(43)

(7,781)

1

 

67,784

(Gains) losses from change in fair market value of equity securities and loan receivable

1,338,190

(1,030,691)

5,883,307

 

(2,210,094)

Losses on equity-method investments

1,633

1,840

2,623

 

3,680

Other non-recurring items

1,161

-

3,970

 

-

Income tax effect on non-GAAP adjustments

(319,518)

213,387

(1,357,228)

 

484,523

Non-GAAP net income

$101,405

$106,585

$250,545

 

$263,956

  

GAAP diluted income (loss) per share

($31.12)

$30.32

($143.88)

 

$62.70

Non-GAAP diluted income per share

$3.38

$3.54

$8.32

 

$8.75

  
  

On a reported basis, net sales for the first half of 2022 decreased 3.6 percent to $1,391.2 million compared to $1,442.7 million for the same period in 2021. On a currency-neutral basis, net sales decreased 0.1 percent.

Year-to-date net loss for 2022 was $4,296.8 million, or $143.8 per share on a fully diluted basis, compared to net income of $1,891.5 million, or $62.70 per share, respectively, during the same period in 2021. On a non-GAAP basis, net income for the first two quarters of 2022 was $250.5 million, or $8.32 per share, compared to $264.0 million, or $8.75 per share, during the same period in 2021.

2022 Financial Outlook

For the full-year 2022, the company now anticipates non-GAAP currency-neutral revenue growth to be at the high end of the prior 1.0 to 2.0 percent guidance, with Covid-related revenue expected to be about $93 million versus approximately $70 million previously. The company is reaffirming its non-GAAP operating margin expectation of approximately 19.0 percent. Bio-Rad’s management will discuss this outlook in greater detail during the second-quarter 2022 financial results conference call.

Share Repurchase Program

On July 28, 2022, Bio-Rad announced that its board of directors authorized increasing the amount available under the company's Share Repurchase Program to allow the company to repurchase up to an additional $200 million of stock. Today, a total of $298.1 million is available for repurchases under the company's program.

Repurchases under the Share Repurchase Program may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The Share Repurchase Program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes, including supporting employee stock plans, funding acquisitions, and minimizing dilution from stock issuances.

Use of Non-GAAP and Currency-Neutral Reporting

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP EPS, which exclude amortization of acquisition-related intangible assets, certain acquisition-related expenses and benefits, restructuring charges, asset impairment charges, gains and losses from change in fair market value of equity securities and loan receivable, gains and losses on equity-method investments, and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. More specifically, management adjusts for the excluded items for the following reasons:

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.

Acquisition-related expenses and benefits: we incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, professional fees for assistance with the transaction; valuation or integration costs; changes in the fair value of contingent consideration, gain or loss on settlement of pre-existing relationships with the acquired entity; or adjustments to purchase price. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our ongoing business.

Restructuring, impairment charges, and gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses on equity-method investments: we incur restructuring and impairment charges on individual or groups of employed assets and charges and benefits arising from gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses on equity-method investments, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our ongoing operations with prior and future periods.

Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters because we do not believe they are reflective of ongoing business and operating results.

Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.

From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.

Percentage sales growth in currency-neutral amounts are calculated by translating prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales.

There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP in the United States. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

Conference Call and Webcast

Bio-Rad’s management will discuss the second quarter ended June 30, 2022 results in a conference call at 3 PM Pacific Time (6 PM Eastern Time) on July 28, 2022. To participate, call 844-200-6205 within the U.S. or +1 929-526-1599 outside the U.S., access code: 715914. A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

BIO-RAD and DROPLET DIGITAL PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 7,900 employees worldwide and $2.9 billion in revenues in 2021. For more information, please visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results; in looking to the second half of the year, expecting the supply chain constraints to continue; remaining on track to achieve our full-year 2022 financial outlook; and for the full-year 2022, anticipating non-GAAP currency-neutral revenue growth to be at the high end of the prior 1.0 to 2.0 percent guidance, with Covid-related revenue expected to be about $93 million versus approximately $70 million previously, and continuing to anticipate non-GAAP operating margin of approximately 19.0 percent. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "anticipate," "estimate," "expect," "continue," "believe," "will," "project," "assume," "may," "intend," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration, severity and impact of the COVID-19 pandemic, global economic conditions, supply chain issues, foreign currency exchange fluctuations, our ability to develop and market new or improved products, our ability to compete effectively, reductions in government funding or capital spending of our customers, international legal and regulatory risks, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Income (Loss)
 
(In thousands, except per share data)
(Unaudited)
 
 

Three Months Ended

 

Six Months Ended

June 30,

 

June 30,

2022

 

2021

 

2022

 

2021

Net sales

$

691,099

 

$

715,931

 

$

1,391,161

 

$

1,442,727

 

Cost of goods sold

 

295,118

 

 

314,333

 

 

591,620

 

 

640,502

 

Gross profit

 

395,981

 

 

401,598

 

 

799,541

 

 

802,225

 

 
Selling, general and administrative expense

 

208,730

 

 

213,425

 

 

406,324

 

 

439,278

 

Research and development expense

 

67,034

 

 

63,391

 

 

129,577

 

 

137,303

 

Income from operations

 

120,217

 

 

124,782

 

 

263,640

 

 

225,644

 

 
Interest expense

 

10,720

 

 

363

 

 

14,768

 

 

761

 

Foreign currency exchange (gains) losses, net

 

897

 

 

(1,761

)

 

(1,231

)

 

(1,690

)

(Gains) losses from change in fair market value of equity securities and loan receivable

 

1,338,190

 

 

(1,030,691

)

 

5,883,307

 

 

(2,210,094

)

Other (income) expense, net

 

(6,710

)

 

96

 

 

(39,307

)

 

(17,311

)

Income (loss) before income taxes

 

(1,222,880

)

 

1,156,775

 

 

(5,593,897

)

 

2,453,978

 

 
Benefit from (provision for) income taxes

 

295,696

 

 

(242,661

)

 

1,297,100

 

 

(562,450

)

Net income (loss)

$

(927,184

)

$

914,114

 

$

(4,296,797

)

$

1,891,528

 

 
Basic earnings (loss) per share:
Net income (loss) per basic share

$

(31.12

)

$

30.71

 

$

(143.88

)

$

63.49

 

 
Weighted average common shares - basic

 

29,794

 

 

29,764

 

 

29,863

 

 

29,793

 

 
Diluted earnings (loss) per share:
Net income (loss) per diluted share

$

(31.12

)

$

30.32

 

$

(143.88

)

$

62.70

 

 
Weighted average common shares - diluted

 

29,794

 

 

30,148

 

 

29,863

 

 

30,167

 

 
Note: As a result of the net loss for the three and six months ended June 30, 2022, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effect was anti-dilutive.
Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
 

June 30,

 

December 31,

2022

 

2021

(Unaudited)

 

 

Current assets:
Cash and cash equivalents

$

596,584

$

470,783

Short-term investments

 

1,376,635

 

404,695

Accounts receivable, net

 

450,324

 

423,537

Inventories, net

 

657,130

 

572,239

Other current assets

 

169,024

 

117,834

Total current assets

 

3,249,697

 

1,989,088

 
Property, plant and equipment, net

 

471,321

 

490,952

Operating lease right-of-use assets

 

185,150

 

204,798

Goodwill, net

 

347,323

 

347,343

Purchased intangibles, net

 

239,747

 

253,939

Other investments

 

8,088,002

 

14,387,006

Other assets

 

100,886

 

102,669

Total assets

$

12,682,126

$

17,775,795

 
Current liabilities:
Accounts payable, accrued payroll and employee benefits

$

338,890

$

418,927

Current maturities of long-term debt

 

466

 

489

Income and other taxes payable

 

25,908

 

46,299

Other current liabilities

 

248,450

 

215,223

Total current liabilities

 

613,714

 

680,938

 
Long-term debt, net of current maturities

 

1,196,943

 

10,514

Other long-term liabilities

 

1,948,872

 

3,417,209

Total liabilities

 

3,759,529

 

4,108,661

 
Total stockholders' equity

 

8,922,597

 

13,667,134

Total liabilities and stockholders' equity

$

12,682,126

$

17,775,795

Bio-Rad Laboratories, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 
 
Six Months Ended
June 30,

2022

2021

 
Cash flows from operating activities:
Cash received from customers

$

1,323,873

 

$

1,456,601

 

Cash paid to suppliers and employees

 

(1,201,166

)

 

(1,131,533

)

Interest paid, net

 

(440

)

 

(1,536

)

Income tax payments, net

 

(86,155

)

 

(77,573

)

Other operating activities

 

60,401

 

 

22,275

 

Net cash provided by operating activities

 

96,513

 

 

268,234

 

 
Cash flows from investing activities:
Payments for purchases of marketable securities and investments

 

(1,478,432

)

 

(255,277

)

Other investing activities

 

425,060

 

 

106,673

 

Net cash used in investing activities

 

(1,053,372

)

 

(148,604

)

 
Cash flows from financing activities:
Proceeds from issuance of Notes, net of debt financing costs

 

1,186,220

 

 

-

 

Payments on long-term borrowings

 

(254

)

 

(1,523

)

Other financing activities

 

(116,999

)

 

(42,959

)

Net cash provided by (used in) financing activities

 

1,068,967

 

 

(44,482

)

 
Effect of foreign exchange rate changes on cash

 

13,666

 

 

(5,102

)

 
Net increase in cash, cash equivalents and restricted cash

 

125,774

 

 

70,046

 

Cash, cash equivalents and restricted cash at beginning of period

 

471,133

 

 

667,115

 

Cash, cash equivalents and restricted cash at end of period

$

596,907

 

$

737,161

 

 
 
Reconciliation of net income (loss) to net cash provided by operating activities:
Net income (loss)

$

(4,296,797

)

$

1,891,528

 

Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization

 

64,625

 

 

66,388

 

Reduction in the carrying amount of right-of-use assets

 

20,008

 

 

19,556

 

(Gains) losses from change in fair market value of equity securities and loan receivable

 

5,883,307

 

 

(2,210,094

)

Changes in working capital

 

(243,442

)

 

(61,418

)

Other

 

(1,331,188

)

 

562,274

 

Net cash provided by operating activities

$

96,513

 

$

268,234

 

Bio-Rad Laboratories, Inc.
Reconciliation of GAAP financial measures to non-GAAP financial measures
(In thousands, except per share data)
(Unaudited)

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS), which exclude amortization of acquisition-related intangible assets; certain acquisition-related expenses and benefits; restructuring charges; asset impairment charges; gains and losses from change in fair market value of equity securities and loan receivable; gains and losses on equity-method investments; and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies.

 

Three Months Ended

 

 

 

Three Months Ended

 

 

 

Six Months Ended

 

 

 

Six Months Ended

 

 

June 30,

 

% of

 

June 30,

 

% of

 

June 30,

 

% of

 

June 30,

 

% of

2022

 

revenue

 

2021

 

revenue

 

2022

 

revenue

 

2021

 

revenue

 
GAAP cost of goods sold

$

295,118

 

$

314,333

 

$

591,620

 

$

640,502

 

Amortization of purchased intangibles

 

(4,450

)

 

(4,640

)

 

(8,911

)

 

(9,225

)

Legal settlements

 

-

 

 

-

 

 

-

 

 

536

 

Restructuring benefits (costs)

 

-

 

 

(1,209

)

 

(3

)

 

(25,189

)

Non-GAAP cost of goods sold

$

290,668

 

$

308,484

 

$

582,706

 

$

606,624

 

 
GAAP gross profit

$

395,981

 

57.3

%

$

401,598

 

56.1

%

$

799,541

 

57.5

%

$

802,225

 

55.6

%

Amortization of purchased intangibles

 

4,450

 

 

4,640

 

 

8,911

 

 

9,225

 

Legal settlements

 

-

 

 

-

 

 

-

 

 

(536

)

Restructuring (benefits) costs

 

-

 

 

1,209

 

 

3

 

 

25,189

 

Non-GAAP gross profit

$

400,431

 

57.9

%

$

407,447

 

56.9

%

$

808,455

 

58.1

%

$

836,103

 

58.0

%

 
GAAP selling, general and administrative expense

$

208,730

 

$

213,425

 

$

406,324

 

$

439,278

 

Amortization of purchased intangibles

 

(1,841

)

 

(2,355

)

 

(3,690

)

 

(4,710

)

Legal matters

 

(875

)

 

(8,761

)

 

(2,068

)

 

(13,176

)

Acquisition related benefits (costs)

 

-

 

 

40

 

 

-

 

 

40

 

Restructuring benefits (costs)

 

(19

)

 

6,929

 

 

(163

)

 

(27,806

)

Other non-recurring items (2)

 

(2,521

)

 

-

 

 

(5,330

)

 

-

 

Non-GAAP selling, general and administrative expense

$

203,474

 

$

209,278

 

$

395,073

 

$

393,626

 

 
GAAP research and development expense

$

67,034

 

$

63,391

 

$

129,577

 

$

137,303

 

Restructuring benefits (costs)

 

62

 

 

2,061

 

 

165

 

 

(14,789

)

Non-GAAP research and development expense

$

67,096

 

$

65,452

 

$

129,742

 

$

122,514

 

 
GAAP income from operations

$

120,217

 

17.4

%

$

124,782

 

17.4

%

$

263,640

 

19.0

%

$

225,644

 

15.6

%

Legal settlements

 

-

 

 

-

 

 

-

 

 

(536

)

Amortization of purchased intangibles

 

6,291

 

 

6,995

 

 

12,601

 

 

13,935

 

Legal matters

 

875

 

 

8,761

 

 

2,068

 

 

13,176

 

Acquisition related (benefits) costs

 

-

 

 

(40

)

 

-

 

 

(40

)

Restructuring (benefits) costs

 

(43

)

 

(7,781

)

 

1

 

 

67,784

 

Other non-recurring items (2)

 

2,521

 

 

-

 

 

5,330

 

 

-

 

Non-GAAP income from operations

$

129,861

 

18.8

%

$

132,717

 

18.5

%

$

283,640

 

20.4

%

$

319,963

 

22.2

%

 
GAAP (gains) losses from change in fair market value of equity securities and loan receivable

$

1,338,190

 

$

(1,030,691

)

$

5,883,307

 

$

(2,210,094

)

Gains (losses) from change in fair market value of equity securities and loan receivable

 

(1,338,190

)

 

1,030,691

 

 

(5,883,307

)

 

2,210,094

 

Non-GAAP (gains) losses from change in fair market value of equity securities and loan receivable

$

-

 

$

-

 

$

-

 

$

-

 

 
GAAP other (income) expense, net

$

(6,710

)

$

96

 

$

(39,307

)

$

(17,311

)

Gains (losses) on equity-method investments

 

(1,633

)

 

(1,840

)

 

(2,623

)

 

(3,680

)

Other non-recurring items (3)

 

1,360

 

 

-

 

 

1,360

 

 

-

 

Non-GAAP other (income) expense, net

$

(6,983

)

$

(1,744

)

$

(40,570

)

$

(20,991

)

 
GAAP income (loss) before income taxes

$

(1,222,880

)

$

1,156,775

 

$

(5,593,897

)

$

2,453,978

 

Legal settlements

 

-

 

 

-

 

 

-

 

 

(536

)

Amortization of purchased intangibles

 

6,291

 

 

6,995

 

 

12,601

 

 

13,935

 

Legal matters

 

875

 

 

8,761

 

 

2,068

 

 

13,176

 

Acquisition related (benefits) costs

 

-

 

 

(40

)

 

-

 

 

(40

)

Restructuring (benefits) costs

 

(43

)

 

(7,781

)

 

1

 

 

67,784

 

(Gains) losses from change in fair market value of equity securities and loan receivable

 

1,338,190

 

 

(1,030,691

)

 

5,883,307

 

 

(2,210,094

)

(Gains) losses on equity-method investments

 

1,633

 

 

1,840

 

 

2,623

 

 

3,680

 

Other non-recurring items (2) (3)

 

1,161

 

 

-

 

 

3,970

 

 

-

 

Non-GAAP income before income taxes

$

125,227

 

$

135,859

 

$

310,673

 

$

341,883

 

 
GAAP benefit from (provision for) income taxes

$

295,696

 

$

(242,661

)

$

1,297,100

 

$

(562,450

)

Income tax effect of non-GAAP adjustments (1)

 

(319,518

)

 

213,387

 

 

(1,357,228

)

 

484,523

 

Non-GAAP provision for income taxes

$

(23,822

)

$

(29,274

)

$

(60,128

)

$

(77,927

)

 
GAAP net income (loss)

$

(927,184

)

-134.2

%

$

914,114

 

127.7

%

$

(4,296,797

)

-308.9

%

$

1,891,528

 

131.1

%

Legal settlements

 

-

 

 

-

 

 

-

 

 

(536

)

Amortization of purchased intangibles

 

6,291

 

 

6,995

 

 

12,601

 

 

13,935

 

Legal matters

 

875

 

 

8,761

 

 

2,068

 

 

13,176

 

Acquisition related (benefits) costs

 

-

 

 

(40

)

 

-

 

 

(40

)

Restructuring (benefits) costs

 

(43

)

 

(7,781

)

 

1

 

 

67,784

 

(Gains) losses from change in fair market value of equity securities and loan receivable

 

1,338,190

 

 

(1,030,691

)

 

5,883,307

 

 

(2,210,094

)

(Gains) losses on equity-method investments

 

1,633

 

 

1,840

 

 

2,623

 

 

3,680

 

Other non-recurring items (2) (3)

 

1,161

 

 

-

 

 

3,970

 

 

-

 

Income tax effect of non-GAAP adjustments (1)

 

(319,518

)

 

213,387

 

 

(1,357,228

)

 

484,523

 

Non-GAAP net income

$

101,405

 

14.7

%

$

106,585

 

14.9

%

$

250,545

 

18.0

%

$

263,956

 

18.3

%

 
GAAP diluted income (loss) per share

$

(31.12

)

$

30.32

 

$

(143.88

)

$

62.70

 

Legal settlements

 

-

 

 

-

 

 

-

 

 

(0.02

)

Amortization of purchased intangibles

 

0.21

 

 

0.23

 

 

0.42

 

 

0.46

 

Legal matters

 

0.03

 

 

0.29

 

 

0.07

 

 

0.44

 

Restructuring (benefits) costs

 

-

 

 

(0.26

)

 

-

 

 

2.25

 

(Gains) losses from change in fair market value of equity securities and loan receivable

 

44.56

 

 

(34.19

)

 

195.40

 

 

(73.26

)

(Gains) losses on equity-method investments

 

0.05

 

 

0.06

 

 

0.09

 

 

0.12

 

Other non-recurring items (2) (3)

 

0.04

 

 

-

 

 

0.13

 

 

-

 

Income tax effect of non-GAAP adjustments (1)

 

(10.64

)

 

7.09

 

 

(45.08

)

 

16.06

 

Add back anti-dilutive shares

 

0.25

 

 

-

 

 

1.17

 

 

-

 

Non-GAAP diluted income per share

$

3.38

 

$

3.54

 

$

8.32

 

$

8.75

 

 
GAAP diluted weighted average shares used in per share calculation

 

29,794

 

 

30,148

 

 

29,863

 

 

30,167

 

Shares included in non-GAAP net income per share, but excluded from GAAP net loss per share as they would have been anti-dilutive

 

238

 

 

-

 

 

246

 

 

-

 

Non-GAAP diluted weighted average shares used in per share calculation

 

30,032

 

 

30,148

 

 

30,109

 

 

30,167

 

 
Reconciliation of Net income (loss) to adjusted EBITDA:
GAAP net income (loss)

$

(927,184

)

-134.2

%

$

914,114

 

127.7

%

$

(4,296,797

)

-308.9

%

$

1,891,528

 

131.1

%

Interest expense

 

10,720

 

 

363

 

 

14,768

 

 

761

 

(Benefit from) provision for income taxes

 

(295,696

)

 

242,661

 

 

(1,297,100

)

 

562,450

 

Depreciation and amortization

 

32,611

 

 

33,652

 

 

64,625

 

 

66,388

 

Foreign currency exchange (gains) losses, net

 

897

 

 

(1,761

)

 

(1,231

)

 

(1,690

)

Other (income) expense, net

 

(6,710

)

 

96

 

 

(39,307

)

 

(17,311

)

(Gains) losses from change in fair market value of equity securities and loan receivable

 

1,338,190

 

 

(1,030,691

)

 

5,883,307

 

 

(2,210,094

)

Dividend from Sartorius AG

 

-

 

 

-

 

 

31,586

 

 

18,991

 

Legal settlements

 

-

 

 

-

 

 

-

 

 

(536

)

Legal matters

 

875

 

 

8,761

 

 

2,068

 

 

13,176

 

Acquisition related (benefits) costs

 

-

 

 

(40

)

 

-

 

 

(40

)

Restructuring (benefits) costs

 

(43

)

 

(7,781

)

 

1

 

 

67,784

 

Other non-recurring items (2)

 

2,521

 

 

-

 

 

5,330

 

 

-

 

Adjusted EBITDA

$

156,181

 

22.6

%

$

159,374

 

22.3

%

$

367,250

 

26.4

%

$

391,407

 

27.1

%

 
 
(1) Excluded items identified in the reconciliation schedule are tax effected by application of a non-GAAP effective tax rate. The non-GAAP tax provision is adjusted for items, the nature of which and/or tax jurisdiction requires the application of a specific tax rate or treatment.
 
(2) Incremental costs to comply with the European Union's In Vitro Diagnostics Regulation ("IVDR") for previously approved products.
 
(3) Gain from the release of an escrow for the sale of a division in 2020.

2022 Financial Outlook

Forecasted non-GAAP operating margin excludes 86 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as foreign currency fluctuations, future gains or losses associated with certain legal matters, acquisitions and restructuring activities.

Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska Schram, Corporate Communications
510-741-6643
cc@bio-rad.com

Source: Bio-Rad Laboratories, Inc.